HGSNAT and mucopolysaccharidosis type 3C: It is tempting to speculate, therefore, that heterologous HSPC transplant used together with small-molecule drugs, either stabilizing a mutant HGSNAT enzyme and increasing its activity levels in the neurons (chaperone therapy) or reducing HS production (substrate reduction therapy), may be an effective component of a combination therapy for MPS IIIC.